October 2, 2013 — Results of EORTC trial 10853 appearing in Journal of Clinical Oncology show that breast conserving treatment combined with radiotherapy reduces the risk of local recurrence in women with ductal carcinoma in situ (DCIS). In the European Organisation for Research and Treatment of Cancer (EORTC) study, adjuvant radiotherapy after local excision reduced the incidence of both in situ and invasive local recurrences by a factor of two and resulted in an overall lower risk of mastectomy.

Long-term outcomes of local recurrences and survival in women receiving radiotherapy in combination with breast conserving surgery for DCIS have been investigated at a median follow-up of 15.8 years.

"Survival after treatment for DCIS is excellent. Therefore, the question rises whether the current treatment for DCIS (local excision and adjuvant radiotherapy of the breast) is overtreatment. To answer this question, not only long-term data about local disease recurrences and prognosis are important, but also information about the prognosis and treatment in case of recurrence," said Mila Donker, M.D., researcher, The Netherlands Cancer Institute.

Between 1986 and 1996, the phase III EORTC trial 10853 randomized 1010 women with complete local excision of DCIS to no further treatment (503 patients) or radiotherapy (507 patients). The risk of any local recurrence reduced by 48% (HR: 0.52, 95%CI 0.40-0.68, P<0.001) in the patients who also received radiotherapy. The 15-year local recurrence-free rate was 69% for the group of patients receiving breast-conserving surgery alone, but this increased to 82% for the group of patients who also received radiotherapy, and the 15-year invasive local recurrence-free rate was 84% versus 90%, respectively (HR: 0.61, 95%CI 0.42-0.87).

The differences observed in local recurrence did not lead to differences in breast cancer specific survival or overall survival, but patients with invasive local recurrence did have a significantly worse breast cancer specific survival (HR: 17.66, 95%CI 8.86–35.18) as well as overall survival (HR: 5.17, 95%CI 3.09-8.66) than those who did not recur. Thus, an invasive recurrence resulted in a worse prognosis.

A lower overall salvage mastectomy rate after a local recurrence was also observed in the group of patients who also received radiotherapy (13%) than in those patients who just received breast conserving surgery (19%). Thus, radiotherapy after breast-conserving surgery for DCIS resulted in an overall lower percentage of patients who were treated with a mastectomy after a local recurrence.

The study highlights the importance of conducting long-term follow-up.

For more information: www.jco.ascopubs.org


Related Content

News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
News | Radiopharmaceuticals and Tracers

Jan. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has launched a national program creating Authorized ...

Time January 30, 2026
arrow
News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Radiology Imaging

Jan. 21, 2026 — Cathpax, a spin-off of the Lemer Pax group that designs, develops and commercializes team-wide, full ...

Time January 22, 2026
arrow
News | Mammography

Jan. 16, 2026 — Vega Imaging Informatics has announced the successful curation of the world’s largest digital breast ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — VizMark has received U.S. Food and Drug Administration FDA 510k clearance for VM1, a non-metal visual ...

Time January 19, 2026
arrow
News | Radiation Therapy

Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and ...

Time January 16, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — Susan G. Komen, the world’s leading breast cancer organization commends Assemblymember Lori Wilson (D ...

Time January 16, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — iSono Health has announced the commercial launch of ATUSA, an FDA-cleared, wearable and automated 3D ...

Time January 14, 2026
arrow
Subscribe Now